Cargando…

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates the continued relevance of COVID-19 convalescent plasma (CCP) therapies. Lessons learnt from previous usage of CCP suggests focusing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sullivan, David J, Franchini, Massimo, Joyner, Michael J., Casadevall, Arturo, Focosi, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387146/ https://www.ncbi.nlm.nih.gov/pubmed/35982681 http://dx.doi.org/10.1101/2021.12.24.21268317

Ejemplares similares

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021)

Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations
por: Franchini, M., et al.
Publicado: (2022)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
por: Focosi, Daniele, et al.
Publicado: (2022)

Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
por: Joyner, Michael J., et al.
Publicado: (2022)

Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects
por: Dulipsingh, Latha, et al.
Publicado: (2023)

COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review
por: Focosi, Daniele, et al.
Publicado: (2021)

Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
por: Belov, Artur, et al.
Publicado: (2022)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
por: Gontu, Abhinay, et al.
Publicado: (2021)

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2021)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
por: Kroemer, Marie, et al.
Publicado: (2022)

COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
por: Sullivan, David, et al.
Publicado: (2023)

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma
por: Salazar, Eric, et al.
Publicado: (2020)

Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
por: McConnell, Scott A., et al.
Publicado: (2023)

Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers
por: Bäuerl, Christine, et al.
Publicado: (2023)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
por: Li, Maggie, et al.
Publicado: (2022)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3di4sj37qrtou7uu9qrnsg9l4s